ABSTRACT
A hallmark of adult hematopoiesis is the continuous replacement of blood cells with limited lifespans. It is well established that adult hematopoietic stem cells (HSCs) are active contributors to these processes after transplantation, yet their role in native hematopoiesis has recently been called into question.
Here, we use inducible lineage tracing from genetically marked adult HSCs to explore their roles in the steady state. We show that adult HSCs contribute robustly to all lineages via intermediate progenitor cells, but with neglible production of hematopoietic cells with a known fetal origin. We further reveal that the timing for regeneration of distinct blood lineages varies substantially.
Finally, HSC contribution to multilineage hematopoiesis in aged animals declines with increasing age. Therefore, while HSCs are active contributors to native adult hematopoiesis, it appears that the numerical increase of HSCs is a physiologically relevant compensatory mechanism to account for a reduced differentiation capacity with age.
INTRODUCTION
HSC-derived hematopoiesis has usually been studied in the setting of transplantation (Benz et al., 2012; Biasco et al., 2016; Dykstra et al., 2007; Lu, Neff, Quake, & Weissman, 2011; Nilsson, Pronk, & Bryder, 2015; Wu et al., 2014) , an experimental paradigm that has been the foundation of hematopoietic research for decades (Siminovitch, McCulloch, & Till, 1963; Till & McCulloch 1961) and which has established hallmark properties of HSCs such as multi-potency and self-renewal. However, while the transplantation assay has provided key insights, not the least with relevance for the clinical use in bone marrow (BM) transplantation, it might not reflect the contribution of HSCs to ongoing and unperturbed steady state hematopoiesis accurately. This is because transplantation is conducted under highly non-physiological conditions wherein HSCs are forced to proliferate to rebuild an entire hematopoietic hierarchy in a myeloablated bone marrow micro-environment.
Therefore, there is a need to approach HSC biology also in more unperturbed settings.
While the overall structure of hematopoiesis is rather well established (Bryder, Rossi, & Weissman, 2006) , the degree by which HSCs contribute to adult hematopoiesis in the steady state is more unclear. This includes whether the proposed differentiation routes for the hematopoietic lineages are obligatory, or whether alternative/complementary pathways exist. Furthermore, cells of the different hematopoietic lineages have not only distinct homeostatic functions and maintenance mechanisms (Bando & Colonna, 2016; Dzierzak & Philipsen, 2013; Rodvien & Mielke, 1976) but also display dramatically different lifespans (Galli, Borregaard, & Wynn, 2011; Harker et al., 2000; Van Putten, 1958; Westera et al., 2013) . As a consequence, the rates by which separate adult-derived blood cell lineages must be replenished differ substantially. At the extreme end, certain hematopoietic cell types generated during the fetal period appear completely devoid of replenishment from adult progenitors, and rather rely on homeostatic proliferation for their maintenance (Ginhoux & Guilliams, 2016; Kantor, Stall, Adams, Watanabe, & Herzenberg, 1995) .
Recent developments of transgenic mouse models that allow for identification (Acar et al., 2015; J. Y. Chen et al., 2016; Gazit et al., 2014) and evaluation of HSCs biology have facilitated studies of native in vivo hematopoiesis (Busch et al., 2015; Sawai et al., 2016; Sun et al., 2014; Wilson et al., 2008) . Using one such model, we recently revealed that most adult HSCs are highly quiescent, which is strikingly different in the transplantation scenario (Säwén et al., 2016) . Other models have been used for lineage tracing from HSCs (Busch et al., 2015; Sawai et al., 2016; Sun et al., 2014) . In one of these, lineage tracing was conducted via random genetic integration of an inducible transposable genetic element, leading to the proposition that native hematopoiesis involves a large number of actively contributing progenitor cell clones, which are only rarely shared among hematopoietic lineages (Sun et al., 2014) . More common approaches for lineage tracing involve the use of cell type specific recombinases, that function to irreversibly mark a cell of interest and with time its descendants. While elegant and extensively used among developmental biologists, such approaches have only sparsely been applied to adult HSCs, and with seemingly contradictory results. Using a Tie2-driven model, Busch et al. concluded a substantial hematopoietic contribution/maintenance from progenitors rather than HSCs (Busch et al., 2015) , which at least to some extent would appear compatible with the results from Sun et al. (Sun et al., 2014) . By contrast, Sawai et al. utilized a Pdzk1ip1-based CreERT2 system and suggested robust HSC labeling and hematopoiesis from adult HSCs (Sawai et al., 2016) .
To try to assess these potential ambiguities, we here investigated the degree to which HSCs contribute to steady state adult hematopoiesis by using an inducible Fgd5-based HSC lineage tracing model (Gazit et al., 2014) . We observed dramatic differences with regards to HSC contribution to adaptive immunity (slow) and the myeloerythroid lineages (fast), with HSCs contributing to the platelet lineage with the most rapid kinetics. The regeneration of terminal cell fates was closely mirrored at the level of each intermediate myeloerythroid precursor. These findings are consistent with adult HSCs as highly active contributors to multilineage hematopoiesis not only following transplantation, but also during the steady state. However, when approached in the situation of chronological aging, we noted diminished mature blood cell output from aged HSCs that could be traced to the first differentiation events from HSCs. These results suggest that the previously proposed fetal to adult switch , in which HSCs alter their properties from more excessive proliferation/differatiation to a more dormant state in the adult, extends gradually throughout adulthood. As a consequence, the well-known numerical increase of HSCs with age (Morrison, Wandycz, Akashi, Globerson, & Weissman, 1996; Rossi et al., 2005; Sudo, Ema, Morita, & Nakauchi, 2000) appears to represent a physiologically relevant mechanism to account for reduced HSC differentiation with age.
RESULTS

Fgd5-CreERT2-based lineage tracing allows for assessment of HSC contributions to unperturbed hematopoiesis
Using a transcriptome based screen of more than 40 different hematopoietic cell types, Fgd5 (FYVE, RhoGEF and PH domain containing 5) was identified as a HSC-expressed gene that is rapidly downregulated upon differentiation.
That Fgd5 expression marks all HSCs was confirmed through functional studies using an Fgd5 knock-in reporter strain (Gazit et al., 2014) . To further detail the HSC specificity of Fgd5, we first acquired transcriptome data from 11,581 individual lineage-marker negative, c-kit positive and CD45 positive bone marrow cells (Linkit + ). The Linkit + population contains a range of different immature hematopoietic progenitor cells (Pronk et al., 2007) .
Therefore, Linkit + cells provided a benchmark to which other more defined/specific hematopoietic progenitor subsets could be compared. Next, we took advantage of an Fgd5 reporter strain in which a ZsGreen-2A-CreERT2 allele was knocked into the endogenous Fgd5 locus (hereafter Fgd5 CreERT2/+ mice) ( Fig. 1B) (Gazit et al., 2014) . We sorted either Linkit + Fgd5 + cells ( Fig. 1A middle; 793 cells, Fgd5 + ), or Fgd5 + cells with a stringent Linkit + Sca-1 + CD48 -CD150 + HSC phenotype (Fig. 1A right, 519 cells, HSC-Fgd5 + ). All Fgd5 + and HSC-Fgd5 + data were aggregated with the Linkit + transcriptome data, which was followed by identification of the most significant gene vectors using principal component analysis (PCA). Data was then visualized using t-distributed stochastic neighbor embedding (tSNE) dimensionality reduction ( Fig. 1A ). Linkit + cells were extensively scattered across the two dimensions ( Fig. 1A, left ), in agreement with the heterogeneity of these cells. By contrast, Fgd5 + cells, regardless if sorted based on additional HSC markers, formed a distinct and highly overlapping cluster (Fig.   1A , middle and right). This cluster localized to a region with very few cells when evaluating Linkit + cells ( Fig. 1A , left, dotted area), emphasizing the HSC-specificity of the Fgd5 reporter and the low HSC frequency within the larger Linkit + fraction.
We next generated a lineage tracing model by crossing Fgd5 CreERT2/+ mice to Rosa26 Tomato/+ mice (Fig. 1B ). In this model, HSCs can be identified based on ZsGreen expression, while Tamoxifen administration leads to irreversible and heritable Tomato labeling of HSCs and, over time, their offspring ( Fig. 1C) . To confirm the model, we evaluated Tomato label in HSC and BM progenitor cells 48 hours after a single injection (1x) of Tamoxifen.
This revealed labeling of a fraction of candidate HSCs, with virtually no labeling in other c-kit + progenitor fractions ( Fig. 1D and Fig. S1 ). This established HSC specific labeling and a relatively low differentiation rate of HSCs in steady state (Säwén et al., 2016; Wilson et al., 2008) . To illustrate our ability to detect Tomato label in peripheral blood (PB) cells, we assessed Tomato expression in defined cell types from mice that had received Tamoxifen 8-48 weeks previously ( Fig. 1D , lower right). Complementary to immunophenotypic identification of initially labeled BM cells as HSCs ( Fig. 1D and data not shown), we evaluated the proliferation history of Tomato labeled HSPCs 5 days after a pulse of Tomato labeling by evaluation of transgenic H2B-mCherry label retention ( Fig. 1E) (Säwén et al., 2016) . Among HSCs, this revealed a strong correlation between a restricted proliferative history and Tomato labeling.
Finally, to corroborate that Tomato labeled phenotypic HSCs are bona fide HSCs, we injected mice with Tamoxifen and isolated candidate Tomato positive and negative HSCs 48 hours later. Sorted cells were transplanted at limiting dilution (5 cells/mouse). This revealed long-term multilineage reconstitution in 5/8 recipients transplanted with Tomato + HSCs (Fig. 1F ).
Fgd5-lineage tracing reveals that HSCs generate different types of hematopoietic progeny with distinct kinetics
Encouraged by the highly specific HSC label observed after Tamoxifen administration to Fgd5 CreERT2/+ Rosa26 Tomato/+ mice ( Fig. 1) , we next set out to perform label tracing studies of hematopoietic generation from HSCs. For this, we labeled cohorts of Fgd5 CreERT2/+ Rosa26 Tomato/+ mice with one injection of Tamoxifen and chased groups of mice for different periods of time up to 83 weeks after labeling. At end point analyses, the fraction of Tomato+ cells was determined in various hematopoietic compartments to assess the HSC contribution to progenitor pools and mature blood cell subsets (Fig. S1 ). The frequencies of Tomato+ cells for each investigated subset were next related to the fraction of Tomato labeled HSC ( Fig. 2A , mean 13% +/-9%) in individual mice ( Fig. 2B, and Fig. S2 ). The fraction of labeled HSCs was generally higher in mice analyzed beyond 4 days of chase compared to mice analyzed after shorter chase periods. However, no further increase in HSC labeling was noted after longer periods of chase ( Fig. 2A ).
First, we investigated Tomato label progression into the immature lineage negative, Sca-1 positive and c-kit positive (LSK) compartment, fractionated further using the Slam markers CD48 and CD150 (Kiel, Yilmaz, Iwashita, Terhorst, & Morrison, 2005) (Fig. 2C and Fig. S1A ). We used this approach to identify HSCs (LSKCD150 + CD48 -) and different multipotent progenitor fractions (MPPs: LSKCD150 -CD48 -, MPP 2 : LSKCD150 + CD48 + , MPP 3/4 : LSKCD150 -CD48 + ).
LSKCD150 -CD48 -MPPs are immature multipotent progenitors distinguished from HSCs by their limited self-renewal potential (Kiel et al., 2005; Kiel, Yilmaz, & Morrison, 2008; Ugale et al., 2014) . Of the evaluated progenitor subsets in our work, this subset was generated from HSCs with the fastest kinetics, with near equilibrium to HSC label reached already by 4 weeks (Fig. 2B ).
MPP 2 cells represent a rare subset of cells with more undefined lineage/developmental affiliations. This prompted us to first elucidate their developmental potential. First, we aimed to place these cells within a transcriptional framework established by other, more established, hematopoietic progenitors. For this, we obtained gene expression data from a panel of defined stem and progenitor cells using a multiplexed qRT-PCR approach for 48 genes, selected to include cell surface markers, cell cycle regulators and transcription factors associated with hematopoiesis (Table S2 ).
This data, along with that from MPP 2 cells, was next visualized using PCA ( Fig. 2C ). This revealed that MPP 2 cells clustered closely to Meg/E progenitors ( Fig. 2C ). Consistent with a close association to the Meg/E lineages, short-term (6 days) culture experiments revealed a more robust generation of both megakaryocyte and erythroid containing colonies from MPP 2 s compared to other LSK subsets ( Fig. S3 ). When investigating Tomato label progression, MPP 2 cells reached label equilibrium with HSCs after 32 weeks in 1x injected mice ( Fig. 2B ).
MPP 3/4 cells lack, for the most part, Meg/E lineage potential (Adolfsson et al., 2005; Arinobu et al., 2007; Pietras et al., 2015; Pronk et al., 2007) . MPP 3/4 cells acquired Tomato label with much slower kinetics compared to other LSK fractions ( Fig. 2B ).
Of the distinct progenitor fractions within the Linkit + fraction ( Mature effector cells represent the terminal progeny of HSCs. We observed distinct generation kinetics for different lineages (Fig. 2B ). First, we made the general observation that myeloerythroid cells acquired label more rapidly than lymphoid cells. Among the myeloid subsets, platelets acquired Tomato label with the fastest kinetics, followed by granulocytes and erythrocytes. Among lymphoid cell types, NK cells displayed faster labeling kinetics followed by B cells. T cells showed the slowest labeling kinetics among lymphoid cells and CD4 + T cells acquired label faster than CD8 + T cells ( Fig. 2B ). Because the frequency of Tomato + cells increased over time in all evaluated lineages, this data demonstrate a continuous contribution of HSCs to all hematopoietic lineages.
While multiple studies have defined populations of hematopoietic progenitors that associate with distinct developmental and/or stages of differentiation (Bryder et al., 2006) , it is unknown whether such described progenitors are obligatory intermediates and/or their quantitative association relative to their anticipated mature offspring. Therefore, we interrogated the relationships between the rates of (re)generation of candidate committed myeloerythroid progenitors to those of their proposed mature cell lineage. At the earliest time points evaluated, we observed for all evaluated fractions a higher label in their corresponding progenitors ( Fig. 2D ). However, this was resolved during the course of the experiments and reached similar equilibrium ratios for all evaluated lineages, although the erythroid lineage displayed somewhat slower kinetics ( Fig. 2D ). Collectively, these experiments are in line with the view that progenitor generation precedes the generation of mature cells and that previously proposed progenitors appears to be, at least for the most part, obligatory intermediates.
Hematopoiesis after transplantation of HSCs is fundamentally different from unperturbed hematopoiesis (Busch et al., 2015; Sun et al., 2014) .
However, to what extent the pre-conditioning regimen and co-transplantation of mature cells and progenitors influence on hematopoiesis from HSCs is less established. Therefore, we next transplanted wild type recipient mice on continuous Tamoxifen diet with purified Fgd5 CreERT2/+ Rosa26 Tomato/+ HSCs or WBM cells. Here, recipient mice were pre-conditioned by either lethal irradiation or antibody mediated CD45-depletion (Palchaudhuri et al., 2016) .
Due to the HSC specificity of the model, this approach allowed us to monitor the kinetics of the HSC contribution to all lineages after transplantation and compare it to the HSC contribution in steady state ( Fig. 2E ). Compared to steady state, label progression in transplanted mice were faster ( Fig. 2E ).
When label progression kinetics was compared between HSC and WBM
transplanted animals, HSC transplantation resulted in faster label progression, especially into the B cell lineage ( Fig. 2E ). This likely reflects a significant contribution to the regeneration of the B cell lineage by co-transplanted longlived B-lineage progenitors and mature cells after WBM transplantation.
Comparison of label progression after WBM transplantation into irradiated or non-irradiated/antibody-mediated conditioned recipient mice revealed similar label progression kinetics into most mature lineages, with the exception of platelets that displayed a faster label progression in WBM transplanted mice.
This suggests that progenitors for platelets are more effectively ablated by irradiation than antibody-mediated pre-conditioning.
Fgd5-mediated HSC lineage tracing corroborates the fetal origin of
Langerhans cells, B1a B cells and brain microglial cells
While a labeling regimen of one Tamoxifen injection allows for accurate kinetic evaluations ( Fig. 2A-B , D), this experimental strategy labels only a fraction of HSCs ( Fig. 2A ) and thus necessitates correlation of label in HSCs to other evaluated cell subsets (Busch et al., 2015) (Fig. 2B ). If the original HSC label is low, this might as a consequence not allow for evaluation of the activity of the entire pool of HSCs.
To explore whether we could label the HSC pool more extensively, Fgd5 CreERT2/+ Rosa26 Tomato/+ mice were fed Tamoxifen containing food pellets for 16 weeks. To rule out adverse effects of prolonged Tamoxifen treatment on HSC proliferation, these experiments were preceded by a control label retaining experiment using H2B-mCherry mice (Säwén et al., 2016) . Following H2B-mCherry induction with Doxycycline, mice were chased for 5 weeks in the presence or absence of Tamoxifen. Prolonged Tamoxifen treatment did not induce any additional proliferation within the HSC compartment, while more differentiated progenitors had readily proliferated in both settings (Fig.   3A ).
The 16 weeks labeling period was followed by an extensive (up to 41 weeks) chase period, during which mice received normal chow (Fig. 3B ). This labeling strategy resulted in labeling of virtually all candidate HSCs (Fig. 3C ).
The blood of labeled mice was analyzed regularly to determine the fraction of Tomato + cells in PB cell subsets ( Fig. S1B ). Similar to after 1x Tamoxifen labeling, we observed robust label progression into all PB cell subsets, with similar kinetics in between different lineages ( Fig. 3B ). However, a more complete HSC labeling resulted in a somewhat faster and more robust label progression into all PB cell subsets compared to 1x Tamoxifen labeling ( Fig.   2E ). This was most evident for the lymphoid lineages, where the majority of PB cells had been generated from HSCs at the experiment end point upon prolonged Tamoxifen administration, whereas the ratio of labeled lymphocytes vs. labeled HSCs was low (> 0,5) even after 83 weeks of chase in 1x
Tamoxifen labeled mice ( Fig. 2 B and E, 3B ).
From endpoint mice in which the pool of HSCs was almost completely labeled ( Fig. 3C ), we next interrogated the skin epidermis for Tomato + contribution to granulocytes and Langerhans cells. Granulocytes were almost completely Tomato positive, while Langerhans cells were devoid of label ( Fig.   3D , lower left), in line with the fetal origin and self-maintenance of the latter cells (Collin & Milne, 2016) . Next, we interrogated Tomato expression in Vγ3δ + T cells, an established fetal derived T cell subset (Havran & Allison, 1990) . To our surprise, this revealed robust Tomato labeling of Vγ3δ + T cells ( Fig. 3D , lower left). However, closer examination revealed high expression of ZsGreen in these cells ( Fig. 3B , lower middle). Therefore, rather than establishing adult contribution to this lineage, these experiments established Fgd5-CreERT2 transgene expression in Vγ3δ + T cells.
B1a B cells represent an invariant subtype of B cells with a fetal origin
that is primarily located in the peritoneum (Hayakawa, Hardy, & Herzenberg, 1985) , where they co-exists with more traditional B1b and B2 B cells in adult mice. While less than 10% of B1a B cells displayed Tomato label, around 50% of B1b B cells and the vast majority of B2 B cells ( Fig. 3D right) were Tomato + (comparable to levels in PB). This is in line with a more strict fetal origin of B1a B cells, the ontogenically mixed origin of B1b B cells (Kantor et al., 1995) and an adult HSC origin of most B2 B cells.
Finally, we investigated adult HSC contribution to microglial cells of the brain, a subset of central nervous system myeloid cells that has been proposed to arise entirely from embryonic precursor cells (Alliot, Godin, & Pessac, 1999) . Evaluations by confocal microscopy of the brain parenchyma revealed no detectable Tomato expression in IBA-1 + microglia (Fig. 3E ), while Fgd5 expressing endothelial cells (Cheng et al., 2012; Gazit et al., 2014) displayed abundant Tomato expression ( Fig. 3E middle) . These results confirm the strict fetal origin of microglia in steady state.
Native hematopoiesis from HSCs declines with aging
We next set out to investigate how chronological aging influence on HSC contribution to hematopoiesis. To achieve rapid and robust labeling of HSCs, we labeled juvenile and aged Fgd5 CreERT2/+ Rosa26 Tomato/+ mice by injecting Tamoxifen for five consecutive days (5x). Labeling was followed by evaluation of the fraction of Tomato+ cells in HSC and MPP fractions of the BM LSK compartment one day after the last Tamoxifen injection.
In aged mice, the initial labeling was highly specific to HSCs, with only low levels of labeling in MPP 2 cells. In sharp contrast, a larger fraction of LSKCD150 -CD48 -MPPs were labeled in juvenile mice (Fig. 4A ). Next we correlated how increasing age influences on the HSC generation of other LSK/MPP subsets. Fgd5 CreERT2/+ Rosa26 Tomato/+ mice between 6 and 96 weeks of age were labeled using a 5x Tamoxifen injection scheme, before evaluation of Tomato label in HSCs/MPP 2-4 21 days later. Ratios of the fraction of labeled MPPs vs. labeled HSCs in corresponding mice was calculated and plotted against mouse age at labeling (Fig. 4B ). This established that label progression into all MPP subsets in aged mice was substantially lower when compared to young adult mice and further revealed that the HSC contribution to MPPs and MPP 3/4 s gradually declines with age towards very little replenishment of in particular MPP 3/4 in very old age (Fig. 4B) .
To evaluate the functional potential of initially Tomato-labeled MPPs, we FACS sorted HSCs and different MPP subsets isolated from non-labeled Fgd5 CreERT2/+ Rosa26 Tomato/+ mice and transplanted cells into lethally irradiated wild type mice. Recipient mice were provided Tamoxifen containing food pellets throughout the experiment. We analyzed donor chimerism and Tomato labeled PB cells after repetitive PB blood sampling. As expected, we did not observe any multilineage long-term reconstitution or Tomato+ cells in MPP 2 /MPP 3/4 transplanted mice ( Fig. 4C ). 10 out of 10 HSC transplanted mice were multi lineage reconstituted at 16 weeks post transplantation with high levels of Tomato+ donor cells in all evaluated lineages ( Fig. 4C ). More surprisingly 2 out of 9 MPP transplanted mice displayed donor reconstitution levels > 1% in all lineages 16 weeks after transplantation (Fig. 4C ). This longterm multilineage reconstitution potential from MPPs was accompanied with robust Tomato labeling among donor cells and revealed that Tomato labeled phenotypic MPPs perform as bona fide HSCs after transplantation ( Fig. 4C ).
By contrast, mice that received MPP cells and displayed only transient myeloid reconstitution never displayed any Tomato+ cells.
Finally, we were interested in determining whether the age-related decrease in HSC derived MPPs might influence on the generation kinetics of lineage-restricted progenitors and mature blood cells. For this, we labeled juvenile (29 days) and aged (87-89 weeks) Fgd5 CreERT2/+ Rosa26 Tomato/+ mice with 1x Tamoxifen, which was followed by evaluation of label progression after 18 weeks ( Fig. 4D and Fig. S4 ). While the frequency of Tomato labeled HSCs was similar among the two groups (Fig. S4 ), all progeny exhibited reduced frequencies of Tomato labeled cells in aged mice, demonstrating a strikingly reduced multilineage differentiation capacity of HSCs as a consequence of age.
DISCUSSION
In this work, we explored the cellular contribution from HSCs using a HSCspecific lineage tracing approach. Our work revealed robust HSC contribution to adult hematopoiesis, while corroborating the fetal origin of other specific hematopoietic subsets. We observed the fastest label progression into the platelet lineage, which might be related to the recent observations that at least a subset of HSCs appears platelet-biased (Sanjuan-Pla et al., 2013; Shin, Hu, Naramura, & Park, 2014) . Thereafter, erythrocytes and granulocytes acquired label with similar kinetics, although Tomato+ erythrocytes emerged in the peripheral blood somewhat later than granulocytes. This likely reflects the slower turnover of mature erythrocytes compared to other myeloid cells. On the other hand, among granulocytes, we did not find any noticeable differences when evaluating HSC contribution to the neutrophil or eosinophil lineages (data not shown), despite the seemingly distinct transcriptional underpinnings of these lineages (Drissen et al., 2016) .
Among lymphocytes, the HSC contribution was most rapid and robust to the NK cell lineage. At present, we can say little on whether this reflects an early and distinct progenitor intermediate for NK cells (Wu et al., 2014) or whether NK cells are, at least partially, regenerated through myeloid progenitors (Q. Chen et al., 2015; Grzywacz, Kataria, Blazar, Miller, & Verneris, 2011) . While the extremely slow HSC generation of adaptive immune components (and T cells in particular) have implications for our understanding of HSCs, by proposing that adult HSCs to a large extent present as myeloid-biased in an unperturbed scenario, our results also suggest the necessity of very harsh conditioning to achieve an "immunological reboot" (the generation of naïve lymphocytes) in certain autoimmune situations (Atkins et al., 2016) .
According to current models of hematopoiesis, lineage committed progenitors reside developmentally in between HSCs and their mature progeny, and much work has been aimed at detailing these stages (Adolfsson et al., 2005; Akashi, Traver, Miyamoto, & Weissman, 2000; Arinobu et al., 2007; Oguro, Ding, & Morrison, 2013; Pietras et al., 2015; Pronk et al., 2007) .
What has remained more unknown is the relationships of these defined progenitors not only to HSCs and their mature offspring, but also whether they are obligatory. In our work, we could demonstrate that the generation rates of each evaluated myeloid progenitor subset correlated highly to their corresponding mature offspring, although the generation kinetics varied depending on lineage. Thus, although some challenges have recently been raised on how lineage commitment occur from HSCs based on inferences from large-scale single-cell RNA sequencing experiments (Paul et al., 2015; Velten et al., 2017) , our data support the more conventional view that the generation of mature myeloid cells is preceded by the generation of obligatory lineage-committed intermediates.
Investigations of immature progenitors revealed that the most rapid label progression associated with LSKCD150 -CD48 -MPPs. MPPs share many defining properties of HSCs, including multilineage differentiation potential and very low proliferation rates in steady state (Säwén et al., 2016) .
The distinction of MPPs from HSCs is mainly thought to result from pronounced differences in self-renewal; a property so far entirely evaluated by transplantation. Intriguingly, our work revealed that LSKCD150 -CD48 -MPPs displayed more rapid label kinetics in young mice, which was gradually declining with advancing age. At the same time, we could in agreement with previous studies (Weksberg, Chambers, Boles, & Goodell, 2008) also demonstrate a minor multilineage HSC activity in this compartment, which correlated exclusively to Fgd5 expression/Tomato labeling. Together with an overall decline in multilineage HSC contribution of aged mice, these results strongly propose a model in which aging associates with reduced/compromised HSC differentiation, which in combination with the wellestablished expansion of HSCs (Morrison et al., 1996; Rossi et al., 2005; Sudo et al., 2000) appears to represent a physiologically relevant compensatory mechanisms to sustain multilineage hematopoiesis from HSCs ( Fig. 4E ).
Compared to MPPs, MPP 3/4 are perhaps easier to approach given their restrictions in lineage potential (lack of Meg/E potential) (Adolfsson et al., 2005; Arinobu et al., 2007; Pietras et al., 2015; Pronk et al., 2007) . We found MPP 3/4 to be regenerated from HSCs with slow kinetics compared to other downstream myeloid progenitor cells, but also to MPP 2 cells, that we in agreement with other studies (Pietras et al., 2015) find "primed" towards Meg/E development. Intriguingly, our data proposes a significant self-renewal activity of at least a subset of MPP 3/4 , with the demonstration that this fraction never reached label equilibrium with HSCs in any evaluated experimental setting. This might be particularly relevant in the setting of age, a situation in which HSC was found to generate MPP 3/4 very inefficiently (Fig. 4E) .
While limited, a few groups have recently approached HSC contribution to native hematopoiesis. Evaluations of hematopoiesis using transposon mobilization led to the conclusion that HSCs are not major contributors to adult hematopoiesis (Sun et al., 2014) . To some degree, this conclusion was later corroborated by CreER-mediated labeling of a minor fraction of the adult HSC pool using a Tie2-based CreER driver (Busch et al., 2015) . Limited HSC contribution to adult hematopoiesis is in sharp contrast to the results we present here and to results from another recent study (Sawai et al., 2016) .
Our studies would propose that absence of a HSC specific driver, as in the work from Sun et al., makes interpretations of HSC contribution very complicated, not the least for the lymphoid lineages, while the labeling of only a minor fraction of HSCs, as in the work from Busch et al., might select for a subset of HSCs with a rather distinct functional behavior.
In summary, we conclude that although the study of native hematopoiesis highlights fundamental differences with in particular slower regeneration times from HSCs to those seen after transplantation, they regardless corroborate decades of research derived from transplantation experiments, in which HSCs has been proposed to continuously contribute to hematopoiesis.
MATERIALS AND METHODS
Mouse procedures
For inducible marking of HSCs in vivo, we crossed Fgd5-2A-ZsGreen-CreERT2 mice (Gazit et al., 2014) Tamoxifen injection (50 mg/kg) and analysis 5 days later.
Tamoxifen was purchased from Sigma-Aldrich and suspended at 100 mg/ml in ethanol and mixed with sunflower oil to a concentration of 10 mg/ml. Tamoxifen was administered by intraperitoneal injections at 50 mg/kg body weight once (1x) or for 5 (5x) consecutive days. To acquire full/maximal HSC labeling, cohorts of mice were continuously fed Tamoxifen containing food pellets for 16 weeks. Mice on Tamoxifen food were regularly bled (sparsely; 1-2 drops) during the labeling period and during the chase period.
Transplanted recipient mice were subjected to lethal irradiation (950 rad) except CD45.1/2 mice that were CD45-depleted by intravenous injection of an immunotoxin (3mg/kg) consisting of CD45.2-biotin (clone 104) and streptavidin-Saporin (Advanced Targeting Systems) in a 1:1 molar ratio 3 days prior to transplantation, as described (Palchaudhuri et al., 2016) . All transplanted cells were isolated from CD45.2 Fgd5 CreERT2/+ Rosa26 Tomato/+ mice. CD45-depleted recipients were transplanted with 10 7 whole bone marrow (WBM) cells and irradiated mice were transplanted with 3 x 10 6 WBM cells (n=7) H2B-mCherry labeling in Col1a1 tetO/tetO ROSA26 H2B-mCherry/H2B-mCherry mice was induced by administration of doxycycline (Säwén et al., 2016) . Thereafter, mice were chased for 5 weeks while eating Tamoxifen containing food pellets or normal chow (No TAM), followed by FACS analysis to assess H2B-mCherry dilution in HSCs/progenitors. All mice were maintained at the animal facilities at BMC at Lund University, and were performed with consent from a local ethical committee.
Immunophenotyping and FACS
Immunophenotyping by FACS was done as described (Säwén et al., 2016) ( Table S1 ). For platelet and erythrocyte analysis, 1 μl of whole blood was taken to 300 μl PBS before FACS analysis. Cells were sorted and/or analyzed on a FACS Aria III cell sorter (Becton Dickinson) or on a LSRFortessa (Becton Dickinson). 
B1a, Langerhans cells and Vg3+ T cell analysis
Immunohistochemistry
Mice were deeply anaesthetized with an overdose of pentobarbital and transcardially perfused with cold saline. Brains were post-fixed for 48 hours in 4% paraformaldehyde (PFA) and incubated in 20% sucrose for 24 hours before being cut in 30 μm thick coronal sections on a microtome. Sections were incubated in blocking solution (5% normal serum and 0.25% Triton X-100 in 0.1 M potassium-phosphate buffered solution) for one hour and subsequently overnight at 4°C with the primary antibody (Iba1 1:1000 Wako).
Fluorophore-conjugated secondary antibody (Molecular Probes or Jackson
Laboratories) was diluted in blocking solution and applied for 2 hours at room temperature. Tomato label could be detected without any staining. Nuclei were stained with Hoechst (Molecular Probes) for 10 minutes and sections were mounted with Dabco mounting medium. Images were obtained using confocal microscopy (Zeiss, Germany).
Cell culture
Single LSKCD150 + CD48 + cells, MPP 3/4 s and HSCs were sorted into Terasaki wells containing 20μl of media (OptiMEM supplemented with 10% FCS, 1:1000 Gentamicin (Invitrogen), 1:100 GlutaMAX (Invitrogen) and 1:500 βmercaptoethanol (Invitrogen) supplemented with cytokines (mSCF (Peprotech) 100ng/ml, TPO (Peprotech) 10ng/ml, IL-3 (Peprotech) 5ng/ml, EPO (Janssen) 5units/ml, human G-CSF (Amgen) 10ng/ml). After 6 days of culture at 37°C, wells were scored and evaluated for the presence of megakaryocytes and erythroid cells by visual inspection in microscope.
Gene expression analyses
qRT-PCR analyses using the Fluidigm Biomark HD Platform was done as described (Säwén et al., 2016) (Table S2 ). PCA on gene expression data from all reference populations was performed using Clustvis, (http://biit.cs.ut.ee/clustvis/).
Single-cell RNA seq libraries were generated using a Chromium system (10x Genomics) according to the manufacturer's instructions. Two consecutive sequencing runs were performed to achieve enough sequencing depth and data was combined and further analyzed using the Cell Ranger TM pipeline (10x Genomics). Single-cell RNA sequencing data will be uploaded to GEO upon publication (accession number X).
Statistical Analysis
Data were analyzed using Microsoft Excel (Microsoft) and Graphpad Prism (GraphPad Software). All FACS analyses were performed using Flowjo software (TreeStar). DB conceived and supervised the study and, together with PS, designed experiments and wrote the manuscript.
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NK cells B cells CD4 T cells
ORGAN NOMENCLATURE PHENOTYPE Bone marrow Myeloid progenitors
Linc-kit + Sca1 -LSK Linc-kit + Sca1 + HSC Linc-kit + Sca1 + CD150 + CD48 -MPP Linc-kit + Sca1 + CD150 -CD48 -MPP 2 Linc-kit + Sca1 + CD150 + CD48 + MPP 3/4 Linc-kit + Sca1 + CD150 -CD48 + MkP Linc-kit + Sca1 -CD150 + CD41 + GMP Linc-kit + Sca1 -CD150 -CD41 -CD16/32 + PreGM Linc-kit + Sca1 -CD150 -CD16/32 -CD41 -CD105 -PreMegE
Linc-kit + Sca1 -CD150 + CD16/32 -CD41 -CD105 -CFU-E Linc-kit + Sca1 -CD150 -CD16/32 -CD41 -CD105 + Peripheral blood
Erythrocytes/RBC FSC mid SSC mid (ter119 + CD45 -CD41 -) Platelets FSC low SSC low (CD41 + CD150 + ) CD4+ T cells CD4 + CD8 -CD8+ T cells CD4 -CD8 + B cells CD4 -CD8 -NK1.1 -CD19 + NK cells CD4 -CD8 -NK1.1 + CD19 -Monocytes CD4 -CD8 -NK1.1 -CD19 -SSC low CD11b + Gr1 neg/low Granulocytes CD4 -CD8 -NK1.1 -CD19 -SSC mid/high CD11b -Gr1 + Myeloid cells CD4 -CD8 -NK1.1 -CD19 -CD11b + Skin
Langerhans cells CD31 -CD45 + Vg3 -TcRgd -F4/80 + Ly6G -Vg3d+ T cells CD31 -CD45 + Vg3 + TcRgd + Granulocytes CD31 -CD45 + Vg3 -TcRgd -F4/80 -Ly6G + Peritoneal cavity B1a CD19 + CD5 + B1b CD19 + CD5 -CD11b + B2 CD19 + CD5 -CD11b -
